Intrathecal Allogeneic B7-H3-Targeted CAR γδ T Cells for Leptomeningeal Metastasis from Solid Tumors: Safety, Efficacy, and Immunologic Dynamics in a Phase I Trial.
Clin Cancer ResOct 1, 2026
Peiwen Ma, Yongxin Zhou, Weiwei Ma et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I trial evaluated the safety and efficacy of intrathecal QH104, an allogeneic B7-H3-targeted CAR γδ T-cell therapy, in 3 patients with leptomeningeal metastasis from solid tumors. The treatment was well tolerated, with no grade ≥ 4 treatment-related adverse events, and all patients exhibited stable disease at days 14 and 30.
Key findings
- No grade ≥ 4 treatment-related adverse events were reported.
- All patients had stable disease at days 14 and 30 according to assessment criteria.
- Cerebrospinal fluid cytology converted to negative in 1 patient with positive baseline cytology.
- B7-H3-CAR γδ T cells persisted in cerebrospinal fluid for at least 1 week.
Why it matters
The study highlights a novel therapeutic approach for leptomeningeal metastasis, a challenging condition with limited treatment options. The findings suggest potential for further development of CAR T-cell therapies in this context.